Login to Your Account



Good Gaucher Data Have Shire Poised to Challenge Cerezyme

By Nuala Moran


Wednesday, August 5, 2009
LONDON - Shire plc is now poised to challenge the blockbuster status of Genzyme's Cerezyme, after reporting positive Phase III data and receiving approval of the treatment protocol, enabling it to start the rolling application of its enzyme replacement for Gaucher's disease under the FDA's fast-track process. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription